Annotated Medicine and Device Lists

Valproic acid (sodium valproate)

Injection 100 mg/mL in 4 mL ampoule Injection 100 mg/mL in 10 mL ampoule Oral liquid 200 mg/5 ml Oral liquid 250 mg/5 mL Oral Solution (drops) 10 mg/drop Solution 250 mg/5 mL Tablet 250 mg Tablet 260 mg Tablet 500 mg Tablet (crushable) 100 mg Tablet (enteric-coated) 200 mg (sodium valproate) Tablet (enteric-coated) 500 mg (sodium valproate)

This medicine is present in:

List	Section	Observation
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	No observations
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.

This medicine is present in:

List	Section	Observation
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	No observations
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	No observations
Bolivia	LINAME 2011 - 2013	No observations
Peru	05. Anticonvulsants/Antiepileptics	No observations
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb

This medicine is present in:

List	Section	Observation
Chile	Essential and Prioritized Medications	No observations
Colombia	13.4 Anticonvulsants	No observations
Venezuela (incomplete)	List of Generic Medications - Venezuela	No observations
Cuba	05. ANTICONVULSIVOS	No observations

This medicine is present in:

List	Section	Observation
Chile	Essential and Prioritized Medications	No observations

This medicine is present in:

List	Section	Observation
Bolivia	LINAME 2011 - 2013	No observations
Peru	05. Anticonvulsants/Antiepileptics	No observations
Ecuador	Essential Medicines List - Ecuador	No observations

This medicine is present in:

List	Section	Observation
Colombia	13.4 Anticonvulsants	No observations

This medicine is present in:

List	Section	Observation
Venezuela (incomplete)	List of Generic Medications - Venezuela	No observations

This medicine is present in:

List	Section	Observation
Cuba	05. ANTICONVULSIVOS	No observations

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	No observations
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	No observations
WHO Model List of Essential Medicines (2021)	24.2.2. Medicines used in bipolar disorders	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
Chile	Essential and Prioritized Medications	No observations

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	No observations
Bolivia	LINAME 2011 - 2013	No observations
WHO Model List of Essential Medicines (2021)	24.2.2. Medicines used in bipolar disorders	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
Peru	05. Anticonvulsants/Antiepileptics	No observations
Peru	24.2.2 For Bipolar Disorder	No observations
Ecuador	Essential Medicines List - Ecuador	No observations
Venezuela (incomplete)	List of Generic Medications - Venezuela	No observations
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Others observations: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb

Information Resources: Valproic acid (sodium valproate)

No information available